The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)

Engensis (donaperminogene seltoplasmid) - Beijing Northland, Reyon Pharma, Helixmith

http://clinicaltrials.gov/ct2/show/NCT05361031

May 4, 2022